计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
A potent bladder relaxant and reagent for diabetes remedy. A potent bladder relaxant compound
Information
Mirabegron (YM 178) is a selectiveβ3-adrenoceptoragonist withEC50of 22.4 nM.
In vitro
Mirabegron concentration-dependently increases the accumulation of cAMP in CHO cells expressing human 3-adrenoceptors (ARs) with I.A. of 0.8. Mirabegron has little agonistic effect on 1- and 2-ARs. Mirabegron concentration-dependently relaxes rat and Human bladder smooth muscle strips precontracted with 10-6 M or 10-7 M carbachol with EC50 values of 5.1 μM and 0.78 μM, respectively. The maximal relaxant effects of Mirabegron are 94.0 % and 89.4% that of carbachol, respectively. Mirabegron is a time-dependent inhibitor of CYP2D6 in the presence of NADPH as the IC50 value in human liver microsomes decreased from 13 to 4.3 μM after 30 min preincubation. Mirabegron acts partly as an irreversible or quasi-irreversible metabolism-dependent inhibitor of CYP2D6.
In vivo
Mirabegron produces a dose-dependent decrease in the frequency of rhythmic bladder contraction in anesthetized rats. 3 mg/kg i.v. Mirabegron suppresses the frequency to 2 counts/10 min. Mirabegron does not decrease the amplitude of rhythmic bladder contraction. Mirabegron decreases primary bladder afferent activity and bladder microcontractions in rats. Mirabegron (0.3 and 1 mg/kg) inhibits mechanosensitive single-unit afferent activities (SAAs) of Aδ fibers in response to bladder filling. SAAs of C-fibers decrease only at 1 mg/kg Mirabegron treatment. Mirabegron administration suppresses the mean bladder pressure and the number of microcontractions during an isovolumetric condition of the bladder. Mirabegron is efficient on facilitation of bladder storage. Mirabegron dose-dependently decreases the resting intravesical pressure. Mirabegron dose dependently decreases the frequency of nonvoiding contractions, considered an index of abnormal response in bladder storage. Mirabegron exhibits no significant effects on the amplitude of nonvoiding contractions, micturition pressure, threshold pressure, voided volume, residual volume, or bladder capacity.
Cell Data
cell lines:NCL-H2106, Colo699 and LNCAP cells
Concentrations:
Incubation Time:
Powder Purity:≥99%
| ALogP | 2.1 |
|---|
H319: 引起严重眼睛刺激
H351: 怀疑会致癌
H373: 长期或反复接触可能对器官造成伤害
H302: 吞食有害
H317: 可能引起皮肤过敏反应
H410: 对水生生物毒性极大并具有长期持续影响
H361: 怀疑破坏生育力或未出生的孩子
H371: 可能对器官造成损害
H362: 可能对母乳喂养的孩子造成伤害
P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾
P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。
P273: 避免释放到环境中。
P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。
P302+P352: 如皮肤沾染:用水充分清洗。
P321: 特殊处理(请参阅此标签上的...)。
P405: 密闭存放
P501: 将内容物/容器送到批准的废物处理厂处理
P264: 处理后要彻底洗手。
P260: 不要吸入灰尘/烟雾/气体/雾/蒸汽/喷雾。
P270: 使用本产品时,请勿进食、饮水或吸烟。
P272: 被污染的工作服不允许离开工作场所
P333+P313: 如发生皮肤刺激或皮疹:求医/就诊。
P362+P364: 脱掉沾污的衣服,清洗后方可重新使用。
P391: 收集溢出物
P330: 漱口
P263: 避免在怀孕期间/哺乳期间接触。
P203: 使用前,获取、阅读并遵守所有安全说明。
P264+P265: 处理后彻底洗手[和…]。不要触摸眼睛。
P301+P317: 如果被吞咽:请寻求医疗帮助。
P318: 如果暴露或担心,请就医。
P337+P317: 如果眼睛刺激持续:寻求医疗帮助。
P308+P316: 如果暴露或担心:立即寻求紧急医疗救助。
P319: 如果你感到不适,请寻求医疗帮助。